


## PHARMACEUTICAL 2019

## KalVista Pharmaceuticals Inc. Rank 127 of 371







## PHARMACEUTICAL 2019

## KalVista Pharmaceuticals Inc. Rank 127 of 371



The relative strengths and weaknesses of KalVista Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of KalVista Pharmaceuticals Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 84% points. The greatest weakness of KalVista Pharmaceuticals Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 25% points.

The company's Economic Capital Ratio, given in the ranking table, is -65%, being 266% points above the market average of -331%.

Input Variable	Value in 1000 USD
Assets, Current	59,380
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	23,216
Liabilities, Non-Current	10,920
Other Assets	173
Other Compr. Net Income	1,534
Other Expenses	0
Other Liabilities	0
Other Net Income	2,900
Property and Equipment	1,836
Research and Development	18,237
Revenues	8,394
Selling, General and Administrative Expense	8,862

Output Variable	Value in 1000 USD
Assets	61,389
Liabilities	34,136
Expenses	27,099
Stockholders Equity	27,253
Net Income	-15,805
Comprehensive Net Income	-15,038
Economic Capital Ratio	-65%